logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Rivaroxaban for reducing the risk of major thrombotic vascular events in symptomatic peripheral arterial disease patients with a recent lower extremity revascularisation procedure

< Back

Rivaroxaban for reducing the risk of major thrombotic vascular events in symptomatic peripheral arterial disease patients with a recent lower extremity revascularisation procedure

Drugs

Cardiovascular Disease and Vascular Surgery

April 2019


Rivaroxaban is in clinical development for reducing the risk of major thrombotic vascular events in patients with symptomatic peripheral arterial disease (PAD) who have undergone a recent lower extremity revascularisation procedure. PAD is a common condition in which a build-up of fatty deposit in the arteries (atherosclerosis) reduces blood supply to the limbs. Many people with PAD have no symptoms but some people develop pain in their legs which may require surgery (revascularisation). People with PAD that undergo this procedure have significantly increased risks of major thrombotic vascular events like heart attack and stroke.
Rivaroxaban is an already approved oral medicine used for the prevention of thrombotic vascular events in different types of artery diseases including PAD. It acts by blocking specific pathways involved in the process of blood clots within blood vessels, reducing the risk of a major vascular event. Aspirin alone is the current standard treatment in patients with PAD undergoing revascularization procedures but its risk reduction may not be adequate. If licensed rivaroxaban will potentially be an option as an add-on therapy in this patient group.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts